107 related articles for article (PubMed ID: 12049334)
41. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas.
Johannessen AL; Torp SH
Pathol Oncol Res; 2006; 12(3):143-7. PubMed ID: 16998593
[TBL] [Abstract][Full Text] [Related]
42. Microvessel density is a prognostic indicator for patients with astroglial brain tumors.
Leon SP; Folkerth RD; Black PM
Cancer; 1996 Jan; 77(2):362-72. PubMed ID: 8625246
[TBL] [Abstract][Full Text] [Related]
43. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
44. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
[TBL] [Abstract][Full Text] [Related]
45. Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma.
Pan JW; Zhan RY; Tong Y; Zhou YQ; Zhang M
J Zhejiang Univ Sci B; 2005 Jul; 6(7):693-8. PubMed ID: 15973775
[TBL] [Abstract][Full Text] [Related]
46. [The expression of hepatocyte growth factor and its receptor in brain astrocytomas].
Chu SH; Yuan XH; Jiang PC; Li ZQ; Zhang J; Wen ZH; Zhao SY; Chen XJ; Cao CJ
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(12):835-8. PubMed ID: 15949402
[TBL] [Abstract][Full Text] [Related]
47. Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors.
Abd El Atti RM; Abou Gabal HH; Osman WM; Saad AS
Diagn Pathol; 2013 Jul; 8():126. PubMed ID: 23902708
[TBL] [Abstract][Full Text] [Related]
48. Aberrant localization of the neuronal class III beta-tubulin in astrocytomas.
Katsetos CD; Del Valle L; Geddes JF; Assimakopoulou M; Legido A; Boyd JC; Balin B; Parikh NA; Maraziotis T; de Chadarevian JP; Varakis JN; Matsas R; Spano A; Frankfurter A; Herman MM; Khalili K
Arch Pathol Lab Med; 2001 May; 125(5):613-24. PubMed ID: 11300931
[TBL] [Abstract][Full Text] [Related]
49. Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas.
Wang M; Tang J; Liu S; Yoshida D; Teramoto A
J Neurooncol; 2005 Jan; 71(1):3-7. PubMed ID: 15719267
[TBL] [Abstract][Full Text] [Related]
50. Quantitative analysis of vessels with smooth muscle layer in astrocytic tumors: correlation with histological grade and prognostic significance.
Sato S; Sato Y; Hatakeyama K; Marutsuka K; Yamashita A; Takeshima H; Asada Y
Histol Histopathol; 2011 Apr; 26(4):497-504. PubMed ID: 21360443
[TBL] [Abstract][Full Text] [Related]
51. Correlation of Ki 67 proliferative index with clinical and pathological features on tissue sections of non Hodgkins lymphoma by immunostaining.
Naz E; Mirza T; Aziz S; Ali A; Danish F
J Pak Med Assoc; 2011 Aug; 61(8):748-52. PubMed ID: 22355994
[TBL] [Abstract][Full Text] [Related]
52. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.
Castellani P; Borsi L; Carnemolla B; Birò A; Dorcaratto A; Viale GL; Neri D; Zardi L
Am J Pathol; 2002 Nov; 161(5):1695-700. PubMed ID: 12414516
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of histological features in diffuse astrocytomas WHO grade II.
Lind-Landström T; Habberstad AH; Sundstrøm S; Torp SH
Int J Clin Exp Pathol; 2012; 5(2):152-8. PubMed ID: 22400076
[TBL] [Abstract][Full Text] [Related]
54. PCNA and Ki-67 labelling indices in pre-irradiated and post-irradiated astrocytomas: a comparative immunohistochemical analysis for evaluation of proliferative activity.
Pierce E; Doshi R; Deane R
Mol Pathol; 1998 Apr; 51(2):90-5. PubMed ID: 9713592
[TBL] [Abstract][Full Text] [Related]
55. Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer.
Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
Virchows Arch; 2006 Jan; 448(1):68-74. PubMed ID: 16220297
[TBL] [Abstract][Full Text] [Related]
56. Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II.
Lind-Landström T; Varughese RK; Sundstrøm S; Torp SH
Diagn Pathol; 2013 Apr; 8():67. PubMed ID: 23618321
[TBL] [Abstract][Full Text] [Related]
57. Overexpression of cyclin A and cyclin B1 proteins in astrocytomas.
Allan K; Jordan RC; Ang LC; Taylor M; Young B
Arch Pathol Lab Med; 2000 Feb; 124(2):216-20. PubMed ID: 10656729
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas--an immunohistochemical study.
Habberstad AH; Gulati S; Torp SH
Diagn Pathol; 2011 May; 6():43. PubMed ID: 21609421
[TBL] [Abstract][Full Text] [Related]
59. Immunohistochemical profile of cystosarcoma phyllodes of the breast: a study of 23 cases.
Dacic S; Kounelis S; Kouri E; Jones MW
Breast J; 2002; 8(6):376-81. PubMed ID: 12390361
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical markers for prognosis of anaplastic astrocytomas.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):203-15. PubMed ID: 12187956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
